Newsroom

CAMPBELL, Calif.--(BUSINESS WIRE)--Mirantis announces its official membership in the Linux Foundation's newly formed Agentic AI Foundation (AAIF) as a Silver Member....

PARIS--(BUSINESS WIRE)--Regulatory News: In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (LEI: 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) declares the following purchases of its own shares (FR0000120271) from December 15 to December 19, 2025: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares...

NEW YORK--(BUSINESS WIRE)--iHeartMedia, the leading audio media company in America, announced today that it will be extending its ‘Creators First’ mission by expanding its podcast platform offerings to seamlessly support both audio and video distribution within both the app and web versions of iHeartRadio -- at no cost to creators. In early 2026, iHeart will give creators the ability to distribute full-length video directly into iHeartRadio – for free – in addition to their existing audio distr...

LAS VEGAS--(BUSINESS WIRE)--emnify, a cloud-native IoT connectivity provider, is introducing a factory-first approach to IoT connectivity that enables devices to connect instantly, reliably, and globally the moment they power on. An award-winning leader in eSIM and IoT connectivity, emnify brings this factory-first approach to CES 2026 to address the growing complexity of IoT manufacturing at scale. Built around Bootstrap Connectivity and a single global eSIM SKU, emnify’s approach allows elect...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, annonce aujourd’hui que la Division pharmaceutique du ministère israélien de la Santé a autorisé l’utilisation, dans le pays, de la thérapie génique candidate GS010/...

PARIS--(BUSINESS WIRE)--Regulatory News: Dans le cadre des autorisations consenties par l’Assemblée générale du 23 mai 2025 pour opérer sur ses actions et conformément à la réglementation relative aux rachats d'actions, TotalEnergies SE (LEI : 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) déclare ci-après les achats d’actions propres (FR0000120271) réalisés du 15 décembre au 19 décembre 2025 : Jour de la transaction Volume total journalier (en nombre de titres) Prix pondéré moyen journ...

WASHINGTON--(BUSINESS WIRE)--The Jack Welch Management Institute at Strayer University (JWMI) was recognized by Poets&Quants as the 9th best online MBA program for 2026....

REDMOND, Wash.--(BUSINESS WIRE)--’Tis the season, and Nintendo is offering more ways to liven up the celebration with the Hits for the Holidays Sale! From now through 11:59 p.m. PT on January 4, 2026, players shopping on Nintendo eShop or My Nintendo Store can save on digital versions of select games for the Nintendo Switch and Nintendo Switch 2 systems. Whether you’re hunting for last-minute gifts or treating yourself to something new, stock up on games for Nintendo Switch, including Princess...

PARIS--(BUSINESS WIRE)--  In accordance with the authorizations given by the shareholders’ general meeting on May 23, 2025, to trade on its shares and pursuant to applicable law on share repurchase, TotalEnergies SE (LEI: 529900S21EQ1BO4ESM68) (Paris:TTE) (LSE:TTE) (NYSE:TTE) declares the following purchases of its own shares (FR0000120271) from December 15 to December 19, 2025: Transaction Date Total daily volume (number of shares) Daily weighted average purchase price of shares (EUR/share) Am...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that Israel’s Ministry of Health Pharmaceutical Division has authorized the use of the candidate gene therapy GS010/LUMEVOQ®1 for the early access treatment of individual patients in the country. Early...